Axcura AG is a Swiss life-science company specializing in the sourcing, qualification, and distribution of pharma and biotech raw materials. We combine Swiss quality, regulatory excellence, and global supplier networks to secure reliable, compliant supply chains.
Products, services, technology
Axcura AG provides sourcing, qualification, and distribution of pharma and biotech raw materials, including APIs, BioPharma ingredients, Advanced Intermediates, and formulation-critical Excipients. Services cover supplier assessment, regulatory documentation, and supply-chain risk management.
Cooperation possibilities
Axcura AG collaborates with biotech companies, CDMOs, and ecosystem partners to support access to qualified raw materials, supply continuity, and regulatory alignment from early development through commercial manufacturing
- https://www.axcura.com/
- +41 55 422 01 01
- Send an email
- Christoph Zahner
Some insights
Axcura AG contributes to resilient and responsible life-science supply chains by enabling access to quality-assured materials. This supports reliable manufacturing of medicines and biotechnological products, helping ensure patient access and continuity of care.
We are proud to build trusted, transparent supply-chain solutions that combine scientific understanding, regulatory responsibility, and long-term partnerships, contributing to resilient biotech manufacturing and reliable access to critical materials.
We see role models in organizations that combine scientific excellence, responsible manufacturing, and long-term thinking—such as leading Swiss biotech innovators, quality-driven CDMOs, and companies that set benchmarks in compliance, sustainability, and collaboration.
Our team’s strengths lie in life-science sourcing, quality and regulatory expertise, and cross-functional project coordination. We aim to further integrate advanced data analytics, digital supply-chain tools, and additional technical depth in bioprocessing.
They would say I help make sure scientists and manufacturers get the right materials at the right time, so medicines can be developed and produced reliably and safely.
By fostering open exchange between innovators, manufacturers, and service providers, supporting early dialogue on regulatory and supply-chain topics, and encouraging collaborative platforms that strengthen resilience across the Swiss biotech ecosystem.
We would like to connect with biotech start-ups and scale-ups, CDMOs, manufacturing and technology partners, quality and regulatory experts, and ecosystem initiatives focused on strengthening resilient and sustainable life-science supply chains.
